Brokers Offer Predictions for RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Ultragenyx Pharmaceutical in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will post earnings per share of ($4.44) for the year. Cantor Fitzgerald has a “Overweight” rating and a $116.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.15) per share.

Several other equities analysts also recently weighed in on the stock. Wedbush reaffirmed a “neutral” rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. JPMorgan Chase & Co. decreased their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. Canaccord Genuity Group reiterated a “buy” rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Finally, Piper Sandler raised their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $92.29.

Ultragenyx Pharmaceutical Stock Up 3.2 %

RARE stock opened at $41.28 on Wednesday. The business’s 50-day moving average price is $44.88 and its 200-day moving average price is $49.63. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. Ultragenyx Pharmaceutical’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($2.23) earnings per share.

Insider Buying and Selling

In related news, CEO Emil D. Kakkis sold 11,727 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This represents a 0.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RARE. True Wealth Design LLC bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $43,000. Values First Advisors Inc. purchased a new stake in Ultragenyx Pharmaceutical in the third quarter worth $56,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $83,000. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter valued at $93,000. Finally, Capital Performance Advisors LLP bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth about $107,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.